Navigation Links
PSA Test Losing Diagnostic Value, Study Says
Date:3/10/2008

Advances in biopsy techniques rendering prostate cancer screen less useful, but some experts disagree

MONDAY, March 10 (HealthDay News) -- Changes in medical practice have undermined the value of the prostate-specific antigen (PSA) test as a diagnostic tool for prostate cancer, a new study asserts.

However, that assertion was immediately challenged by other experts in the field.

The American Cancer Society recommends annual screening for prostate cancer for most men after age 50. The screening is done in two steps: a digital rectal exam, followed by a blood test for PSA, a protein produced by the prostate gland.

"In men with an abnormal digital rectal examination, it [the PSA test] still is very predictive," said study author Dr. Douglas S. Scherr, clinical director of urological oncology at Weill Cornell Medical Center in New York City. "For men with a normal digital rectal examination, it has lost the predictive accuracy it had in the 1990s."

For those men, exact PSA readings matter less, because doctors are doing more biopsies now and are using improved biopsy techniques, Scherr explained. His report was expected to be published in the April 15 issue of Cancer. In a retrospective analysis, his team looked at 1,607 prostate biopsies performed at Weill Cornell between 1993 and 2005, and uncovered several trends.

In the 1990s, biopsies generally were limited to men with PSA readings higher than 4 nanograms per milliliter of blood. Later, they were often done when the PSA levels were between 2.5 and 4, Scherr said.

"In the early and mid-90s, we used six needles when we did a biopsy," he said. "Now, we stick in 14. Taking more cores and doing biopsies at lower PSA levels has allowed us to keep the prostate cancer detection level steady. If we kept the PSA level at 4 rather than at 2.5, the cancer detection rate would have fallen rapidly."

Increased awareness of prostate cancer has also changed the screening picture, Scherr said. "You almost never have an abnormal rectal examination these days," he said.

There is a need to develop new biomarkers for prostate cancer beyond PSA, Scherr said. "Should a man when he turns 50 have a biopsy?" he said. "It is certainly an important question that needs being looked at."

But the study merely "makes a statistical point about an unusual population," said Andrew Vickers, a statistician whose title at Memorial Sloan-Kettering Cancer Center in New York is attending research methodologist.

"It apples to men who have regular screening," Vickers said. "It doesn't apply to men who haven't been screened. For those men, the PSA test might be more accurate."

And the study is misleading because of information it doesn't contain, said Dr. Ian M. Thompson, chairman of urology at the University of Texas Health Science Center at San Antonio.

The study includes only men on whom biopsies were done, Thompson said. "If you don't biopsy something, you don't know if you have cancer or not," he said. "The study is informative only of men who had biopsies. There is nothing in it about the criteria they used to recommend biopsies."

Risk factors for prostate cancer, such as ethnicity, age and family history, are not mentioned in the study, Thompson added. "You don't know anything about the people in their practice who never had a biopsy," he noted.

The PSA test has flaws, Thompson acknowledged. Most notably, it is unable to distinguish between prostate cancers that will grow so slowly that they do not endanger life and those that are aggressive enough to kill.

"But of all the tools we currently have, the PSA test is valuable," he said. "People dealing with other kinds of cancer wish they had a blood test like PSA."

More information

You can learn about the diagnosis and treatment of prostate cancer from the National Cancer Institute.



SOURCES: Douglas S. Scherr, M.D., clinical director, urological oncology, Weill Cornell Medical Center, New York City; Andrew Vickers, Ph.D., statistician, Memorial Sloan- Kettering Cancer Center, New York City; Ian M. Thompson, chairman, urology, University of Texas Health Science Center, San Antonio; April 15, 2008, Cancer


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Top Tips to Enjoy Healthy Latin Food Without Losing the Taste (Recipe)
2. IRIDEX Announces Closing of $5.0 Million Private Placement
3. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
4. Cruel Deaths in Mexico a Result of Closing U.S. Horse Processing Plants: AVMA
5. Bionovo Announces Closing of Public Offering of Common Stock
6. PA Residents Losing Employer Coverage at Rate Second Only to CA
7. Physicians Hail VNUS Device for Closing Diseased Perforating Veins
8. Biopure Announces Closing of $14.9 Million Financing
9. Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
10. AMICAS Solutions Closing the Loop in Radiology Communications
11. Shreveport, LA Mother Wins $10,000 for Losing 50 Pounds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PSA Test Losing Diagnostic Value, Study Says
(Date:2/27/2017)... ... February 27, 2017 , ... Much attention has been paid to the ... dependent on opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from ... in fatal overdoses in male populations.(1) , The proportion of women using illicit drugs ...
(Date:2/27/2017)... Yorba Linda, Ca (PRWEB) , ... February 27, ... ... Coulter Life Sciences, provides an overview on laser diffraction analysis as a tool ... highlighting its capabilities, significance and potential to obtain improved results and novel scientific ...
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health ... British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition ... Alsager, showcases the Centre's commitment to innovation in drug rehab and alcohol treatment ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination ... and concern over nerve agents and the deadly use of chemical weapons. Many questions ... and how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC ... North America, today announced it would be offering some it’s exclusive product line ... on crafting quality and unique baby clothing/feeding products, will team up with AMAZON ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)... 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... Co., Ltd., received a positive response from the ... design for RGN-137 to treat epidermolysis bullosa ("EB"). ... incorporates Thymosin beta 4 ("Tß4") as the active ...
(Date:2/27/2017)... 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... M.D., Ph.D., as President and Chief Executive Officer (CEO) and ... Dr. Craig succeeds Richard Love , interim President and ... of Directors.  Dr. Craig has over 20 years of experience ... and Europe . "On behalf ...
Breaking Medicine Technology: